Myung-Ju Ahn1, Chun-Ming Tsai2, Frances A Shepherd3, Lyudmila Bazhenova4, Lecia V Sequist5, Toyoaki Hida6, James C H Yang7, Suresh S Ramalingam8, Tetsuya Mitsudomi9, Pasi A Jänne10, Helen Mann11, Mireille Cantarini12, Glenwood Goss13. 1. Section of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 2. Department of Oncology, Taipei-Veterans General Hospital and School of Medicine, National Yang-Ming University, Taipei, Taiwan. 3. Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, Ontario, Canada. 4. Department of Medicine, University of California-San Diego, Moores Cancer Center, La Jolla, California. 5. Department of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts. 6. Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. 7. Department of Oncology, National Taiwan University Hospital, National Taiwan University Cancer Center, Taipei City, Taiwan. 8. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia. 9. Department of Thoracic Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. 10. Lowe Center for Thoracic Oncology, The Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts. 11. Biometrics and Information Science, AstraZeneca, Cambridge, United Kingdom. 12. Global Medicines Development, AstraZeneca, Alderley Park, United Kingdom. 13. Division of Medical Oncology, The Ottawa Hospital Cancer Center, University of Ottawa, Ottawa, Ontario, Canada.
Abstract
BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is selective for both EGFR-TKI-sensitizing and T790M (threonine-to-methionine substitution at codon 790)-resistance mutations. The authors present long-term follow-up data from a preplanned, pooled analysis of phase 2 studies, the AZD9291 First Time in Patients Ascending Dose Study (AURA) extension trial (clincialtrials.gov identifier NCT01802632) and the AURA2 trial (NCT02094261). METHODS: Patients with centrally confirmed, T790M mutation-positive, advanced non-small cell lung cancer received osimertinib 80 mg once daily until disease progression or study discontinuation. Response was assessed by a blinded, independent, central review using Response Evaluation Criteria in Solid Tumors, version 1.1. The primary endpoint was the objective response rate. RESULTS: In total, 411 patients received osimertinib (second line, 129 patients; third line or later, 282 patients). At the data cutoff date of November 1, 2016, the median treatment exposure was 16.4 months (range, 0-29.7 months), the objective response rate was 66% (95% confidence interval [CI], 61%-70%), the median response duration was 12.3 months (95% CI, 11.1-13.8 months), and the median progression-free survival was 9.9 months (95% CI, 9.5-12.3 months). At the data cutoff date of May 1, 2018, 271 patients (66%) had died, and 140 patients (34%) had discontinued before death. The median overall survival was 26.8 months (95% CI, 24.0-29.1 months); and the 12-month, 24-month, and 36-month survival rates were 80%, 55%, and 37%, respectively. Grade ≥3 possibly causally related (investigator assessed) adverse events were reported in 65 patients (16%), and the most common were rash (grouped terms; 42%; grade ≥3, 1%) and diarrhea (39%; <1%). CONCLUSIONS: This pooled analysis represents the most mature clinical trial data for osimertinib in patients with pretreated, T790M-positive, advanced non-small cell lung cancer, further establishing osimertinib as a standard of care for this patient population.
BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is selective for both EGFR-TKI-sensitizing and T790M (threonine-to-methionine substitution at codon 790)-resistance mutations. The authors present long-term follow-up data from a preplanned, pooled analysis of phase 2 studies, the AZD9291 First Time in Patients Ascending Dose Study (AURA) extension trial (clincialtrials.gov identifier NCT01802632) and the AURA2 trial (NCT02094261). METHODS: Patients with centrally confirmed, T790M mutation-positive, advanced non-small cell lung cancer received osimertinib 80 mg once daily until disease progression or study discontinuation. Response was assessed by a blinded, independent, central review using Response Evaluation Criteria in Solid Tumors, version 1.1. The primary endpoint was the objective response rate. RESULTS: In total, 411 patients received osimertinib (second line, 129 patients; third line or later, 282 patients). At the data cutoff date of November 1, 2016, the median treatment exposure was 16.4 months (range, 0-29.7 months), the objective response rate was 66% (95% confidence interval [CI], 61%-70%), the median response duration was 12.3 months (95% CI, 11.1-13.8 months), and the median progression-free survival was 9.9 months (95% CI, 9.5-12.3 months). At the data cutoff date of May 1, 2018, 271 patients (66%) had died, and 140 patients (34%) had discontinued before death. The median overall survival was 26.8 months (95% CI, 24.0-29.1 months); and the 12-month, 24-month, and 36-month survival rates were 80%, 55%, and 37%, respectively. Grade ≥3 possibly causally related (investigator assessed) adverse events were reported in 65 patients (16%), and the most common were rash (grouped terms; 42%; grade ≥3, 1%) and diarrhea (39%; <1%). CONCLUSIONS: This pooled analysis represents the most mature clinical trial data for osimertinib in patients with pretreated, T790M-positive, advanced non-small cell lung cancer, further establishing osimertinib as a standard of care for this patient population.
Keywords:
AZD9291 First Time in Patients Ascending Dose Study (AURA); epidermal growth factor receptor (EGFR); osimertinib; pooled analysis; threonine-to-methionine mutation at codon 790 (T790M); tyrosine kinase inhibitor (TKI)
Authors: Flávia Melo Cunha de Pinho Pessoa; Caio Bezerra Machado; Emerson Lucena da Silva; Laudreísa da Costa Pantoja; Rodrigo Monteiro Ribeiro; Maria Elisabete Amaral de Moraes; Manoel Odorico de Moraes Filho; Raquel Carvalho Montenegro; André Salim Khayat; Caroline Aquino Moreira-Nunes Journal: Int J Mol Sci Date: 2022-03-30 Impact factor: 5.923
Authors: A Cortellini; A Leonetti; A Catino; P Pizzutillo; B Ricciuti; A De Giglio; R Chiari; P Bordi; D Santini; R Giusti; M De Tursi; D Brocco; F Zoratto; F Rastelli; F Citarella; M Russano; M Filetti; P Marchetti; R Berardi; M Torniai; D Cortinovis; E Sala; C Maggioni; A Follador; M Macerelli; O Nigro; A Tuzi; D Iacono; M R Migliorino; G Banna; G Porzio; K Cannita; M G Ferrara; E Bria; D Galetta; C Ficorella; M Tiseo Journal: Clin Transl Oncol Date: 2019-08-07 Impact factor: 3.405
Authors: Helena A Yu; Luis G Paz-Ares; James Chih-Hsin Yang; Ki Hyeong Lee; Pilar Garrido; Keunchil Park; Joo-Hang Kim; Dae Ho Lee; Huzhang Mao; Sameera R Wijayawardana; Ling Gao; Rebecca R Hozak; Bo H Chao; David Planchard Journal: Clin Cancer Res Date: 2020-10-12 Impact factor: 12.531